康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06185 康希诺生物

交易中 05-15 13:20:36

27.700

-0.200

-0.72%

最高27.900	最低27.180	成交量63.42万
今开27.800	昨收27.900	日振幅2.58%
总市值68.43亿	流通市值36.75亿	总股本2.47亿
成交额1,744万	换手率0.48%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":27.7,"timestamp":1778822397477,"preClose":27.9,"halted":0,"volume":634200,"delay":0,"changeRate":-0.007168458781361982,"floatShares":132670900,"shares":247043801,"eps":0.11,"marketStatus":"交易中","change":-0.2,"latestTime":"05-15 13:20:36","open":27.8,"high":27.9,"low":27.18,"amount":17444620,"amplitude":0.025806,"askPrice":27.7,"askSize":7800,"bidPrice":27.66,"bidSize":18000,"shortable":3,"etf":0,"ttmEps":-0.005,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778832600000},"marketStatusCode":2,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":27.9,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":0.510009,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":59.78,"timestamp":1778822422000,"preClose":61.01,"halted":0,"volume":1638600,"delay":0,"premium":"-59.77"}},"requestUrl":"/m/hq/s/06185/wiki","defaultTab":"wiki","newsList":[{"id":"2634016296","title":"智通AH统计|5月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2634016296","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634016296?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:27","pubTimestamp":1778574421,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月12日收盘，东北电气、浙江世宝、中石化油服分列AH溢价率前三位，溢价率分别为513.64%、344.81%、302.60%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-19.99%、-16.60%、-4.65%。其中大唐发电、晨鸣纸业、南华期货股份的偏离值位居前三，分别为59.58%、36.27%、34.90%；另外，东北电气、长飞光纤光缆、中芯国际的偏离值位居后三，分别为-53.05%、-21.38%、-20.29%。　　前十大AH股溢价率排行。　　股票名称H股(港元)A股溢价率↓偏离值","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260512/32217919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01276","00568","399300","03143","02238","01349","02465","EWH","00991","03986","00588","00386","03145","03750","159982","06196","03328","03908","PNGAY","PAImain","06680","02318","00981","00187","01800","02899","01033","02338","02359","02628","02691","06185","00042","01057","02218","HPAD.SI","01108","03968","03678","01812","82318","00553","01766","06869","601318","03996","02701","00300","688981"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634140182","title":"康希诺生物(06185)：青少年及成人用Td5cp的NDA获国家药监局药品审评中心纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2634140182","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634140182?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:48","pubTimestamp":1778489303,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，公司为其吸附无细胞百(五组分)白破联合疫苗的新药上市申请获得中国国家药品监督管理局药品审评中心纳入优先审评。根据国家优先审评审批的规定，国家药监局药品审评中心对纳入优先审评审批的NDA，将优先配置资源进行审评。青少年及成人用Td5cp适用于6岁及以上人群，为青少年及成人的百白破加强疫苗。公司正在准备青少年及成人用Td5cp的NDA递交工作","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)：青少年及成人用Td5cp的NDA获国家药监局药品审评中心纳入优先审评","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1191","BK1515","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135659717","title":"康希诺生物4月股份变动月报表出炉，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1135659717","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135659717?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:52","pubTimestamp":1778057574,"startTime":"0","endTime":"0","summary":"康希诺生物股份公司于2026年5月6日发布2026年4月股份变动月报表。公告显示，截至2026年4月30日，公司已发行股份总数与上月保持一致，股本结构整体未发生变化。根据月报披露，康希诺生物现有普通股股本分为H股和A股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631858486","title":"瑞银：降康希诺生物(06185)目标价至52.4港元 首季业绩符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2631858486","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631858486?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:55","pubTimestamp":1777535726,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，康希诺生物(06185)今年首季业绩符合预期。期内，收入为1.9亿元人民币(下同)，同比增长38.7%，略高于该行预测2026年全年34%的增长; 净亏损为4,000万元，对比该行预测今年全年盈利3.37亿元。瑞银调整集团2026年至2028年每股盈利预测，由原先的1.36元、2.26元及3.77元分别下调至0.77元、2.15元及3.58元。目标价由59.8港元下调至52.4港元;评级“买入”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194176889","title":"异动解读 | 首季净亏损同比扩大250%，康希诺生物盘中大跌5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194176889","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194176889?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:01","pubTimestamp":1777431664,"startTime":"0","endTime":"0","summary":"康希诺生物今日盘中股价大幅下挫，跌幅达5.87%，引起了市场的广泛关注。消息面上，公司发布了第一季度财务报告，业绩表现不佳是导致股价承压的主要原因。报告显示，公司归属于上市公司股东的净亏损为4042.43万元人民币，与去年同期相比，亏损幅度惊人地扩大了250.13%。尽管期内营业收入实现了38.73%的同比增长，达到1.9亿元，但巨额的亏损扩大以及经营活动产生的现金流量净额为净流出6702.16万元，加剧了投资者对公司盈利能力和现金流状况的担忧，从而引发了抛售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170599465","title":"康希诺生物2026年第一季度财报营收1.90亿元，经调整净利润-5511.52万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170599465","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170599465?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:03","pubTimestamp":1777367026,"startTime":"0","endTime":"0","summary":"根据康希诺生物发布的2026年第一季度报告，报告期内，公司实现营业收入1.90亿元人民币，较上年同期增长38.73%。其中，四价流脑结合疫苗“曼海欣”保持较高销量，13价肺炎球菌多糖结合疫苗“优佩欣”成功上市后也贡献了可观收入，国际技术转移及中间品销售业务则成为新的收入增长点。经调整净利润方面，本期归属于上市公司股东的扣除非经常性损益后的净亏损为-5511.52万元。研发投入合计7669.96万元，占营业收入比例为40.31%，同比下降24.52个百分点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物2026年第一季度财报营收1.90亿元，经调整净利润-5511.52万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630799123","title":"康希诺生物(06185)一季度归母净亏损4042.43万元 同比扩大250.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630799123","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630799123?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:59","pubTimestamp":1777366795,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物(06185)发布截至2026年3月31日止3个月业绩，营业收入1.9亿元(人民币，下同)，同比增加38.73%;归属于上市公司股东的净亏损4042.43万元，同比扩大250.13%;每股基本亏损0.16元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"530716c61aaa22cfcffdb04a123fa588","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"康希诺生物(06185)一季度归母净亏损4042.43万元 同比扩大250.13%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","06185","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627184954","title":"中国首个三组分百白破疫苗获批，康希诺生物成长逻辑跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2627184954","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627184954?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:19","pubTimestamp":1776151191,"startTime":"0","endTime":"0","summary":"盼康欣®的获批，不仅是康希诺生物产品矩阵中又一款重磅新品的落地，深层则是对公司创新技术平台厚度、管线梯度构建能力与商业化体系效率的集中验证。","market":"us","thumbnail":"https://img2.gelonghui.com/37500-65516e94-e8c5-4b46-9002-7a60e38e1725.jpg?guru_height=853&guru_width=1280&guru_size=129556","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/37500-65516e94-e8c5-4b46-9002-7a60e38e1725.jpg?guru_height=853&guru_width=1280&guru_size=129556"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4407500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","BK1515","BK0239","06185","159646","BK1574","BK1191","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627389104","title":"智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧","url":"https://stock-news.laohu8.com/highlight/detail?id=2627389104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627389104?lang=zh_cn&edition=full","pubTime":"2026-04-13 07:18","pubTimestamp":1776035912,"startTime":"0","endTime":"0","summary":"牌照于今日生效。伊美第三轮谈判已结束 双方存在严重分歧总台记者当地时间12日获悉，伊朗与美国在伊斯兰堡举行的又一轮会谈已结束。伊朗方面消息称，伊朗与美国代表团在谈判中仍存在一些严重分歧。美伊谈判21小时未达成协议。盛宝银行首席投资策略师 Charu Chanana 表示，美伊谈判无果而终是一次倒退。美英担忧 AI 暴露金融业漏洞Anthropic 发布 AI 模型 Mythos 预览版，美国政府日前召集一批银行高管紧急开会，讨论相关问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7d08dbda469a470286c6f9b045c09156","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["C","CRCD","01729","ICRC","09995","BK4023","LU1791807156.HKD","LU1861559042.SGD","LU1861217088.USD","BK1161","LUMN","00005","06088","BK1596","LU1668664300.SGD","BK1500","01773","AVGO","BK1228","LU0106831901.USD","LU1969619763.USD","603083","CRCG","688331","CRCO","AMD","BK1583","HSBC","LU1861220207.SGD","LU1861558580.USD","06185","LU2328871848.SGD","06869","BK1574","300748","06166","BAC","WFC","06680","LU2360107671.USD","BK4588","NVDA","AMZN","BK4585","688185","03317","CRCA","BK1556","06960","CCUP","601869"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626172927","title":"康希诺生物(06185)：婴幼儿用DTcP获得中国国家药监局NDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626172927","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626172927?lang=zh_cn&edition=full","pubTime":"2026-04-12 18:07","pubTimestamp":1775988440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 公布，中国国家药品监督管理局已批准公司研发的婴幼儿用吸附无细胞百(三组分)白破联合疫苗的新药上市申请。公司的婴幼儿用DTcP为国内首款上市的组分百白破疫苗。公司的婴幼儿用DTcP为公司组分百白破疫苗产品组合中首个获得NDA批准的产品，公司累积了临床研发、质量控制、规模化生产等相关经验，有利于产品组合中其他候选疫苗上市进程的推进。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)：婴幼儿用DTcP获得中国国家药监局NDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","06185","BK1191","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912492","title":"【券商聚焦】中信建投维持康希诺生物(06185)“买入”评级 指MCV4销售放量驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625912492?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:35","pubTimestamp":1775640940,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，康希诺生物 2025年业绩符合预期，核心产品四价流脑结合疫苗销售放量驱动收入增长，降本增效措施推动公司归母净利润实现扭亏。维持对公司的“买入”评级。2026年2月，MCV4曼海欣的适用人群年龄范围获批扩大至6周岁，有利于提升市场渗透率。MCV4已于2025年9月实现向印度尼西亚的首批发运，并在当地进行临床试验。展望2026年，预计MCV系列产品将保持稳健增长，PCV13i的上市销售及持续准入有望带来业绩增量。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ODNhNzQzNTMwNTQ2MTgyMzE4MDgzODg2OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ODNhNzQzNTMwNTQ2MTgyMzE4MDgzODg2OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978411","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192168799","title":"康希诺生物更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1192168799","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192168799?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:36","pubTimestamp":1775118981,"startTime":"0","endTime":"0","summary":"2026年4月2日，康希诺生物发布截至2026年3月31日的股份变动月报表。公告显示，公司本月未有新增发行、回购或注销股份，整体股本结构保持不变。公司全称为康希諾生物股份公司。报告期内，法定/注册股本总额为人民币247,043,801元。其中，H股法定/注册股份数为132,670,900股，A股法定/注册股份数为114,372,901股，两类股份数量均与上月一致，且已发行股本均无变化。截至3月末，公司并无任何股份购回活动或注销事宜，已发行股本总数保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142883845","title":"异动解读 | 康希诺生物盘中大涨9.68%，业绩扭亏为盈及流脑疫苗收入增长提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1142883845","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142883845?lang=zh_cn&edition=full","pubTime":"2026-04-01 12:50","pubTimestamp":1775019015,"startTime":"0","endTime":"0","summary":"康希诺生物(06185)今日盘中大幅上涨9.68%，引起了市场的广泛关注。消息面上，公司发布了年度业绩报告，显示全年实现营业收入10.59亿元人民币，同比增长28.43%；并实现扭亏为盈，公司拥有人应占溢利为2787.30万元人民币。此外，公司还公布了未来三年的股东分红回报规划，明确了现金分红优先的原则，增强了投资者信心。业绩增长主要得益于其核心产品——中国首款四价流脑结合疫苗“曼海欣”的收入持续增长。公司通过坚持创新与商业化并重的发展战略，深入推进降本增效，优化产销协同，从而持续提升了经营效率。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624956661","title":"港股异动 | 康希诺生物(06185)午前涨近10% 流脑疫苗收入持续增长 全年纯利实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2624956661","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624956661?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:56","pubTimestamp":1775015783,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康希诺生物(06185)午前涨近10%，截至发稿，涨9.49%，报34.16港元，成交额2834.76万港元。消息方面，康希诺生物发布年度业绩。全年实现营业收入10.59亿人民币元，同比增长28.43%；本公司拥有人应占溢利2787.30万人民币元 ，同比扭亏为盈。此外，公司发布未来三年股东分红回报规划，明确现金分红优先原则。公告显示，报告期内，业绩增长主要得益于公司核心产品中国首款四价流脑结合疫苗曼海欣的收入持续增长；公司通过持续践行以创新为核心、以商业化为重点的发展战略，深入推进降本增效，同时优化了产销协同，经营效率持续提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1574","06185","BK1161","BK4588","159646","BK1515","BK1191","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623478333","title":"康希诺生物(06185)公布2025年业绩 实现收入约10.59亿元 同比增长28.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623478333","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623478333?lang=zh_cn&edition=full","pubTime":"2026-03-31 00:07","pubTimestamp":1774886865,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 公布2025年业绩，收入约10.59亿元，同比增长28.43%;年内利润2787.3万元，同比扭亏为盈;每股盈利0.11元。自2022年推出四价流脑结合疫苗曼海欣和二价流脑结合疫苗美奈喜以来，两款疫苗为预防婴幼儿流脑疾病提供了更为高效、优质的疫苗选择。2025年，随着流脑疫苗产品的推广和市场导入，两款流脑结合疫苗实现销售收入约9.677亿元，同比增长21.9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)公布2025年业绩 实现收入约10.59亿元 同比增长28.43%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","06185","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618909611","title":"每日卖空追踪 | 康希诺生物 03月11日卖空量成交5800股，卖空比例为1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618909611","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618909611?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217837,"startTime":"0","endTime":"0","summary":"康希诺生物北京时间03月11日，跌2.29%，卖空量成交5800股，较上一交易日减少88.63%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163547a6b796a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163547a6b796a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06185","BK1161","BK1574","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618090966","title":"康希诺生物03月11日主力净流出62.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618090966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618090966?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216948,"startTime":"0","endTime":"0","summary":"03月11日, 康希诺生物股价跌2.29%，报收34.06元，成交金额1181.7万元，换手率0.26%，振幅3.96%，量比0.50。康希诺生物今日主力资金净流出62.0万元，上一交易日主力净流入52.7万元。该股近5个交易日上涨7.58%，主力资金累计净流入203.6万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出82.2万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161931a460aa83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161931a460aa83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06185","BK1574","BK1161","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618512929","title":"全国政协委员、康希诺生物首席科学官朱涛：医防融合 进一步强化青少年及成人疫苗接种工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2618512929","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618512929?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:45","pubTimestamp":1773153943,"startTime":"0","endTime":"0","summary":"构建并完善全生命周期免疫规划体系。以“十四五”收官总结与“十五五”规划谋划为关键契机，推动免疫规划从“婴幼儿重点覆盖”向“全人群动态保障”转型，建立基于疾病负担监测数据的青少年及成人疫苗接种动态评估机制，按疾病危害程度、人群感染风险适时扩大免疫规划疫苗品类与覆盖年龄范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667812167.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667812167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","BK1191","06185","BK1515","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617507452","title":"港股异动 | 康希诺生物(06185)涨超5% 生产基地获得马来西亚PIC/S GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2617507452","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617507452?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:00","pubTimestamp":1772780457,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康希诺生物涨超5%，截至发稿，涨5.53%，报33.98港元，成交额2325.1万港元。消息面上，康希诺生物昨晚公布，公司自主研发的ACYW135群脑膜炎球菌多糖结合疫苗曼海欣和13价肺炎球菌多糖结合疫苗优佩欣生产基地通过了马来西亚药监局PIC/S GMP符合性检查，并于近日获得NPRA颁发的GMP证书。公司指，此次通过PIC/S GMP认证，标志着康希诺生物的生产和质量管理体系已达到国际药品检查合作组织GMP标准要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK1574","06185","BK4585","BK1515","BK1191","VT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617917512","title":"康希诺生物(06185)获得PIC/S GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2617917512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617917512?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:57","pubTimestamp":1772701020,"startTime":"0","endTime":"0","summary":"PIC/S为国际药品检查、认证的权威机构，由数十个国家的药品监管机构组成，以统一标准对人用和兽用药品的GMP实施检查、认证，GMP符合性检查是药品注册上市的必要条件之一。在自愿的基础上，PIC/S成员国及参与机构之间执行 GMP符合性检查互认。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06185","BK1191","BK1515","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.1672},{"period":"3month","weight":-0.1657},{"period":"6month","weight":-0.3935},{"period":"1year","weight":-0.124},{"period":"ytd","weight":-0.201}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":0.02},{"period":"3month","weight":-0.0067},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1163},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.030578},{"month":2,"riseRate":0.857143,"avgChangeRate":0.172684},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.060436},{"month":4,"riseRate":0.625,"avgChangeRate":0.049828},{"month":5,"riseRate":0.25,"avgChangeRate":-0.04292},{"month":6,"riseRate":0.571429,"avgChangeRate":0.037423},{"month":7,"riseRate":0.571429,"avgChangeRate":0.056212},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.143307},{"month":9,"riseRate":0.714286,"avgChangeRate":0.068326},{"month":10,"riseRate":0.428571,"avgChangeRate":0.059174},{"month":11,"riseRate":0.571429,"avgChangeRate":0.088604},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.035813}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}